Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 10, 2014; 5(3): 382-392
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.382
Significance of immunohistochemistry in breast cancer
Dana Carmen Zaha
Dana Carmen Zaha, Preclinical Department, Faculty of Medicine and Pharmacy, Oradea University, Oradea 410087, Romania
Author contributions: Zaha DC performed the data collection, analysis and wrote the paper.
Correspondence to: Dana Carmen Zaha, MD, PhD, Lecturer, Preclinical Department, Faculty of Medicine and Pharmacy, Oradea University, 1 December Square, No.10, Oradea 410087, Romania. danazaha @rdslink.ro
Telephone: +40-723-604496 Fax: +40-723-604496
Received: December 26, 2013
Revised: February 9, 2014
Accepted: June 18, 2014
Published online: August 10, 2014
Processing time: 217 Days and 22.4 Hours
Core Tip

Core tip: Immunohistochemistry has an important role in the pathology of breast disease, as well as in other benign or malignant tumours. There is a growing list of available products (antibodies) or antigen retrieval techniques, which all contribute to the broader utility of immunohistochemistry for solving diagnostic problems or for determining prognosis and response to therapy in breast pathology. Myoepithelial markers are useful in helping to distinguish benign lesions from malignant lesions. The most common immunohistochemical breast cancer prognostic and therapeutic markers used include: estrogen receptor, human epidermal growth factor receptor-2, Ki-67, progesterone receptor, and p53. In addition, markers of angiogenesis and apoptosis are also important.